Patents by Inventor William L. Laswell

William L. Laswell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 6040317
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Wasyl Halczenko, Melissa S. Egbertson, George D. Hartman, William L. Laswell
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5880136
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: March 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5814643
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: September 29, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5658929
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: August 19, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Fibrinogen receptor antagonists
    Patent number: 5294616
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: March 15, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, Laura M. Turchi, William L. Laswell
  • Nitrogen deprotected 4-acyloxyazetidin-2-ones
    Patent number: 5177201
    Abstract: The 4-acyloxyazetidin-2-ones, which are intermediates in the production of carbapenems and penems, are produced from nitrogen deprotected 4-furanylazetidin-2-ones.
    Type: Grant
    Filed: June 21, 1990
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, William L. Laswell, Ralph P. Volante, Ichiro Shinkai
  • Stereoselective synthesis of a chiral cis 3-beta hydrogen (3R) 4-aroyloxy azetidinone
    Patent number: 5145957
    Abstract: A process is described for the stereocontrolled synthesis of (3R,4R)-3-[(1R)-1-hydroxyethyl]-4-benzoyloxyazetidin-2-ones and their derivatives by cycloaddition involving an imine and a ketone, generated from 3(S)-hydroxybutyrate which are useful intermediates in the synthesis of carbapenem antibiotics.
    Type: Grant
    Filed: January 9, 1992
    Date of Patent: September 8, 1992
    Assignee: Merck & Co., Inc.
    Inventors: David M. Tschaen, Joseph E. Lynch, William L. Laswell, Ralph P. Volante, Ichiro Shinkai
  • Process for the preparation of 4-acyloxyazetidin-2-one by electrochemical methods
    Patent number: 4952288
    Abstract: The 4-acryloxyazetidin-2-ones, which are intermediates in the production of carbapenems and penems, are produced from 4-furanylazetidin-2-ones by electrochemical methods.
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: August 28, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, Ralph P. Volante, William L. Laswell, Ichiro Shinkai
  • Process for the preparation of 4-acyloxyazetidin-2-one by singlet oxygen oxidation
    Patent number: 4940520
    Abstract: The 4-acyloxyazetidin-2-ones, which are intermediates in the production of carbapenems and penems, are produced from 4-furanylazetidin-2-ones by singlet oxygen oxidation.
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: July 10, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, William L. Laswell, Ralph P. Volante, Ichiro Shinkai
  • Oxidation and reduction method to produce 4-acyloxyazetidin-2-one
    Patent number: 4923982
    Abstract: The 4-acyloxyazetidin-2-ones, which are intermediates in the production of carbapenems and penems, are produced from 4-furanylazetidin-2-ones by a sequential oxidation-reduction-oxidation reaction scheme.
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: May 8, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, William L. Laswell, Ralph P. Volante, Ichiro Shinkai